Business Wire

NV-ESI-GROUP

7.1.2020 08:02:14 CET | Business Wire | Press release

Share
Farasis Energy Breaks Through the Electric Vehicle Market Thanks to ESI’s Virtual Prototyping

ESI Group (Paris:ESI), leading innovator in Virtual Prototyping software and services for manufacturing industries, helped Farasis Energy, a Chinese-American battery provider, win in record-breaking time, a call for tenders made by a premium German automotive OEM. Thanks to ESI’s expertise, the reliability of the virtual prototype of the new Farasis battery model was decisive in a “zero real prototype” procedure, stipulating the elimination of any physical prototype.

The move of the automotive industry toward electrification is seemingly unstoppable. Manufacturers are announcing aggressive plans for Electric Vehicle (EV) production, and the International Energy Agency says the number of EVs will grow from 3 to 125 million by 2030. So, it’s no wonder that new players are entering the market, breaking the traditional rules of product design – new players like lithium-ion battery maker Farasis Energy. Looking to collect wins in this fast-growing market, the team at Farasis relied on ESI’s expertise to prove to a major German car maker that they were the best supplier – based solely on a virtual prototype. This collaboration around ESI’s Virtual Performance Solution (VPS) allowed to virtualize and secure the behavior of the battery in vibration or vehicle crash situations.

Dr. Matt Klein, Advanced R&D Director at Farasis Energy, emphasized the key role ESI played in this project: “Half-way through the bidding process, the manufacturer actually decided to remove the physical prototype step – they would make their decision based on the virtual prototype. In just 8 months, we went from limited Virtual Prototyping capability to winning those bids. The head of the whole program conducting the bidding process went out of his way to tell us that the mechanical simulation was an instrumental part in helping us get the design approved. We could not have done that without ESI. Our partnership with ESI is truly strategic in bringing our simulation capabilities to a global leading standard.”

Two fundamental elements differentiated ESI’s VPS in this project:

  • The reliability of the results, eliminating the need for a real prototype verification, as a result of the consideration of complex physical phenomenon inside the battery.
  • The integration level of different virtual vibration and crash tests in one solution, allowing iteration loops and quick decisions.

Farasis relied on ESI’s proven knowledge of the automotive industry and ability to provide real results, virtually, thanks to virtual prototyping. The capability to build a global model, covering several engineering disciplines, led to a highly efficient workflow and ultimately a cost-effective solution for Farasis.

Since their win, Farasis has opened a new factory on-site in Germany, dedicated to the research & development of their batteries for the German car maker. ESI is now putting in place a platform for Farasis’ international team of simulation engineers, one that is fully automated and customized to their way of working. Thanks to this Platform, the Farasis team will work together – regardless of what continent they are on – with great efficiency and transparency, on common Virtual Prototyping models. And what began as a bi-lateral partnership has quickly evolved into an ecosystem comprised of three major players – Farasis, ESI Group, and the automotive manufacturer – all hungry to tap into the EV market.

About Farasis

Farasis Energy, Inc. created in California in 2002 is a company specialized in the conception and distribution of batteries. Present in China (headquarters), in the Silicon Valley (R&D center), and in Europe, the Group is one of the world leaders in his sector. Farasis’ ambition is to position itself as a pivot to better meet the challenges of its industrial clients: saving time to market and the costs of production while maintaining a high level of reliability and safety.

ESI and Farasis will jointly showcase their expertise and partnership at the CES 2020 in Las Vegas. Meet them in ESI Booth: LVCC, Automotive Section - North Hall, booth #9020

About ESI Group

ESI Group is a leading innovator in Virtual Prototyping software and services. Specialist in material physics, ESI has developed a unique proficiency in helping industrial manufacturers replace physical prototypes by virtual prototypes, allowing them to virtually manufacture, assemble, test and pre-certify their future products. Coupled with the latest technologies, Virtual Prototyping is now anchored in the wider concept of the Product Performance Lifecycle™, which addresses the operational performance of a product during its entire lifecycle, from launch to disposal. The creation of a Hybrid Twin™, leveraging simulation, physics and data analytics, enables manufacturers to deliver smarter and connected products, to predict product performance and to anticipate maintenance needs.

ESI is a French company listed in compartment B of NYSE Euronext Paris. Present in more than 40 countries, and addressing every major industrial sector, ESI Group employs about 1200 high-level specialists around the world and reported annual sales of €139 million in 2018. For more information, please visit www.esi-group.com .

Follow ESI
LinkedIn
Facebook
Twitter
YouTube

Contact:

ESI Group Shan Florence Barré press@esi-group.com +33 1 49 78 28 28

Lola Gozlan lola.gozlan@shan.fr +33 6 24 76 83 40

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye